Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Top Stories > Bavarian says mpox vaccine approved by EU regulator for adolescents
    Top Stories

    Bavarian says mpox vaccine approved by EU regulator for adolescents

    Published by Jessica Weisman-Pitts

    Posted on September 19, 2024

    2 min read

    Last updated: January 29, 2026

    This image depicts the Bavarian Nordic mpox vaccine, recently approved by the EU regulator for adolescents. The approval aims to enhance immunization efforts against mpox in vulnerable age groups amid the ongoing outbreak.
    Bavarian Nordic mpox vaccine approved by EU for adolescents - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:Public Health

    Quick Summary

    LONDON (Reuters) -Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU’s drug regulator for use in adolescents, bolstering the case for using the shot in the 12 to 17 age group to contain an outbreak in parts of Africa.

    LONDON (Reuters) -Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU’s drug regulator for use in adolescents, bolstering the case for using the shot in the 12 to 17 age group to contain an outbreak in parts of Africa.

    Mpox has been declared a global public health emergency by the World Health Organization (WHO), with children and adolescents being particularly vulnerable to the disease.

    Bavarian’s JYNNEOS has also been approved by the U.S. Food and Drug Administration (FDA) but only for adults 18 years and older, although it granted an Emergency Use Authorization for its use in adolescents during the mpox outbreak of 2022.

    Its approval by the Committee for Medicinal Products for Human Use (CHMP), draws on data submitted by the Danish biotech firm to the European Medicines Agency (EMA) last month.

    “We applaud EMA for their expedited review and decision to recommend approval,” said Bavarian CEO Paul Chaplin.

    While the WHO says the vaccine can be used “off-label” for people below 18, it has only backed its use in adults.

    WHO approval can guide domestic choices, as well as allowing international aid groups to buy and distribute a vaccine.

    Democratic Republic of Congo (DRC), worst-hit by the current outbreak, is not planning to vaccinate under-18 year olds in its first wave of immunisations with the Bavarian vaccine.

    Another mpox vaccine, made by the Japan’s KM Biologics, can already be given to children, according to the Japanese regulator, although it requires a special kind of needle.

    While the EMA decision does not officially guide countries outside Europe, Congo referred to its evaluation of Bavarian’s vaccine in its June emergency use approval of the shot domestically. It also mentioned the FDA approval.

    Since this outbreak began in January, there have been nearly 25,100 cases and more than 720 deaths in Africa, where the country reporting the most cases is the DRC, the WHO says.

    (Reporting by Maggie Fick, editing by Terje Solsvik and Alexander Smith)

    Frequently Asked Questions about Bavarian says mpox vaccine approved by EU regulator for adolescents

    1What is a vaccine?

    A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. It typically contains an agent that resembles a disease-causing microorganism.

    2What is mpox?

    Mpox, formerly known as monkeypox, is a viral disease that can cause fever, rash, and swollen lymph nodes. It is primarily transmitted through close contact with an infected person.

    3What is the European Medicines Agency (EMA)?

    The European Medicines Agency (EMA) is an agency of the European Union responsible for the evaluation and supervision of medicinal products. It ensures that medicines are safe and effective.

    More from Top Stories

    Explore more articles in the Top Stories category

    Image for Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Image for Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Image for Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Image for Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Image for Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Image for Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Image for Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Image for PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    Image for A Notable Update for Employee Health Benefits:
    A Notable Update for Employee Health Benefits:
    Image for Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Image for Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Image for ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    View All Top Stories Posts
    Previous Top Stories PostUK retail sales rise by more than expected in August
    Next Top Stories PostUK reports sharpest rise in health-related welfare claims, study shows